Ken Griffin Acurx Pharmaceuticals, Inc. Transaction History
Citadel Advisors LLC
- $505 Billion
- Q3 2024
A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Acurx Pharmaceuticals, Inc. stock. As of the latest transaction made, Citadel Advisors LLC holds 9,200 shares of ACXP stock, worth $7,452. This represents 0.0% of its overall portfolio holdings.
Number of Shares
9,200
Previous 14,200
35.21%
Holding current value
$7,452
Previous $31,000
45.16%
% of portfolio
0.0%
Previous 0.0%
Shares
3 transactions
Others Institutions Holding ACXP
# of Institutions
26Shares Held
1.25MCall Options Held
9.3KPut Options Held
9.7K-
Vanguard Group Inc Valley Forge, PA529KShares$428,7720.0% of portfolio
-
Prospect Financial Services LLC Melville, NY295KShares$239,0100.35% of portfolio
-
Geode Capital Management, LLC Boston, MA147KShares$118,6650.0% of portfolio
-
Morgan Stanley New York, NY46.2KShares$37,4220.0% of portfolio
-
Lpl Financial LLC Fort Mill, SC44.8KShares$36,2710.0% of portfolio
About Acurx Pharmaceuticals, Inc.
- Ticker ACXP
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 11,556,600
- Market Cap $9.36M
- Description
- Acurx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections. Its lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that has completed Phase II clinical trial to treat patients with clostridium difficile infections. The com...